A Phase 3 Trial of Upadacitinib for Giant-Cell Arteritis
New England Journal of Medicine · 29.05.2025 · 392 (20) · 2013-2024
DOI: 10.1056/nejmoa2413449 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 29.05.2025. Verfasst von Daniel Blockmans und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Internal Medicine, University Hospitals Leuven, Leuven, Belgium. Hauptthemen laut MEDLINE: Giant Cell Arteritis, Glucocorticoids, Janus Kinase Inhibitors. Die Arbeit wurde bisher 114-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: AbbVie.
Abstract (Originalsprache)
BACKGROUND: Giant-cell arteritis is a systemic vasculitis with limited treatment options. The efficacy and safety of upadacitinib - a selective Janus kinase (JAK) inhibitor that blocks the signaling of several cytokines, including interleukin-6 and interferon-γ - are unknown in patients with giant-cell arteritis. METHODS: We randomly assigned patients with new-onset or relapsing giant-cell arteritis, in a 2:1:1 ratio, to receive upadacitinib at a dose of 15 mg or 7.5 mg orally once daily plus a 26-week glucocorticoid taper or placebo plus a 52-week glucocorticoid taper. The primary end point was sustained remission at week 52, defined by the absence of signs or symptoms of giant-cell arteritis from week 12 through week 52 and adherence to the protocol-specified glucocorticoid taper. RESULTS: A total of 209 patients received upadacitinib at a dose of 15 mg, 107 received upadacitinib at a dose of 7.5 mg, and 112 received placebo; 70% of the patients had new-onset giant-cell arteritis. Upadacitinib at a dose of 15 mg showed superiority over placebo with respect to the primary end point (46.4% [95% confidence interval {CI}, 39.6 to 53.2] vs. 29.0% [95% CI, 20.6 to 37.5]; P = 0.002). Upadacitinib at a dose of 15 mg was superior to placebo in the analysis of the hierarchically prespecified and multiplicity-controlled key secondary end points of sustained complete remission, time to a disease flare, cumulative glucocorticoid exposure, and patient-reported outcomes. Upadacitinib at a dose of 7.5 mg was not superior to placebo with respect to the primary end point (41.1% [95% CI, 31.8 to 50.4]). Safety outcomes during the treatment period of 52 weeks were similar in the upadacitinib and placebo groups. Although cardiovascular risk is a potential concern with a JAK inhibitor, no major adverse cardiovascular events occurred in the upadacitinib groups. CONCLUSIONS: In patients with giant-cell arteritis, upadacitinib at a dose of 15 mg - but not 7.5 mg - with a 26-week glucocorticoid taper showed efficacy superior to that of placebo with a 52-week glucocorticoid taper. (Funded by AbbVie; SELECT-GCA ClinicalTrials.gov number, NCT03725202.).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of General Internal Medicine, University Hospitals Leuven, Leuven, Belgium.
- Department of Microbiology, Immunology, and Transplantation, KU Leuven, Leuven, Belgium.
- AbbVie, North Chicago, IL.
- Immanuel Krankenhaus Berlin, Medical Center for Rheumatology Berlin-Buch, Berlin.
- Division of Rheumatology and Immunology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.
- Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark.
ORCID-Profile: Andrea Rubbert-Roth
Förderung
- AbbVie
Zitieren
APA
Blockmans, D., Penn, S. K., Setty, A. R., Schmidt, W. A., Rubbert-Roth, A., Hauge, E. M., Keen, H. I., Ishii, T., Khalidi, N., Dejaco, C., Cid, M. C., Hellmich, B., Liu, M., Zhao, W., Lagunes, I., Romero, A. B., Wung, P. K., Merkel, P. A., & SELECT-GCA Study Group (2025). A Phase 3 Trial of Upadacitinib for Giant-Cell Arteritis. New England Journal of Medicine, 392(20), 2013-2024. https://doi.org/10.1056/nejmoa2413449
Vancouver
Blockmans D, Penn SK, Setty AR, Schmidt WA, Rubbert-Roth A, Hauge EM, et al. A Phase 3 Trial of Upadacitinib for Giant-Cell Arteritis. New England Journal of Medicine. 2025;392(20):2013-2024. doi:10.1056/nejmoa2413449
BibTeX
@article{Blockmans2025,
author = {Blockmans, Daniel and Penn, Sara K and Setty, Arathi R and Schmidt, Wolfgang A and Rubbert-Roth, Andrea and Hauge, Ellen M and Keen, Helen I and Ishii, Tomonori and Khalidi, Nader and Dejaco, Christian and Cid, Maria C and Hellmich, Bernhard and Liu, Meng and Zhao, Weihan and Lagunes, Ivan and Romero, Ana B and Wung, Peter K and Merkel, Peter A and SELECT-GCA Study Group, SELECT-GCA Study Group},
title = {A Phase 3 Trial of Upadacitinib for Giant-Cell Arteritis},
journal = {New England Journal of Medicine},
year = {2025},
volume = {392},
number = {20},
pages = {2013--2024},
doi = {10.1056/nejmoa2413449}
}
EUVIMED